Literature DB >> 23549633

A common gene variant in PLS3 predicts colon cancer recurrence in women.

Joanna Szkandera1, Thomas Winder, Michael Stotz, Melanie Weissmueller, Tanja Langsenlehner, Martin Pichler, Hellmut Samonigg, Wilfried Renner, Armin Gerger, Gudrun Absenger.   

Abstract

Recent evidence suggests that PLS3 (T-Plastin), an important member of the actin filamentous network, significantly influences cell invasion and metastasis. Germline polymorphisms within the PLS3 gene may impact the gene's function, resulting in inter-individual differences in tumor recurrence capacity. In the present study, we investigated the association of germline polymorphisms in PLS3 to predict time to recurrence (TTR) in patients with stage II and III colon cancer. A total of 264 patients with histologically confirmed colon cancer were included in this retrospective study. Germline DNA was genotyped for rs871773 C>T, rs757124 C>G, rs1557770 G>T, rs6643869 G>A, and rs2522188 C>T in the PLS3 gene by 5'-exonuclease (TaqMan™) technology. As the PLS3 gene is located on the X chromosome, a gender-specific statistical analysis was performed. In univariate analysis, the minor allele of PLS3 rs871773 C>T was significantly associated with decreased TTR in women (hazard ratio (HR) = 5.02; 95 % confidence interval (CI) = 1.251-20.114; p = 0.023) and remained significantly associated in multivariate analysis (HR = 6.165; 95 % CI = 1.538-24.716; p = 0.010). Female patients carrying the C/T genotype in PLS3 rs871773 showed a median TTR of 69 months. In contrast, female patients with homozygous C/C had a median TTR of 112 months. There were no significant associations between PLS3 rs871773 C>T and TTR in male and between the other polymorphisms and TTR in male or female colon cancer patients. In conclusion, we identified a common gene variant in PLS3 as an independent prognostic marker in female patients with stage II and III colon cancer. Larger prospective trials are warranted to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23549633     DOI: 10.1007/s13277-013-0754-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  17 in total

1.  Cancer incidence and mortality in Europe, 2004.

Authors:  P Boyle; J Ferlay
Journal:  Ann Oncol       Date:  2005-02-17       Impact factor: 32.976

2.  T-plastin (PLS3) gene expression differentiates Sézary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression.

Authors:  N Tang; H Gibson; T Germeroth; P Porcu; H W Lim; H K Wong
Journal:  Br J Dermatol       Date:  2009-11-30       Impact factor: 9.302

Review 3.  Medical aspects of the actin cytoskeleton.

Authors:  P A Janmey; C Chaponnier
Journal:  Curr Opin Cell Biol       Date:  1995-02       Impact factor: 8.382

4.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

5.  Increased expression of T-plastin gene in cisplatin-resistant human cancer cells: identification by mRNA differential display.

Authors:  T Hisano; M Ono; M Nakayama; S Naito; M Kuwano; M Wada
Journal:  FEBS Lett       Date:  1996-11-11       Impact factor: 4.124

6.  Search for genes involved in UV-resistance in human cells by mRNA differential display: increased transcriptional expression of nucleophosmin and T-plastin genes in association with the resistance.

Authors:  Y Higuchi; K Kita; H Nakanishi; X L Wang; S Sugaya; H Tanzawa; H Yamamori; K Sugita; A Yamaura; N Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1998-07-30       Impact factor: 3.575

7.  Molecular cloning and characterization of plastin, a human leukocyte protein expressed in transformed human fibroblasts.

Authors:  C S Lin; R H Aebersold; S B Kent; M Varma; J Leavitt
Journal:  Mol Cell Biol       Date:  1988-11       Impact factor: 4.272

8.  Human plastin genes. Comparative gene structure, chromosome location, and differential expression in normal and neoplastic cells.

Authors:  C S Lin; T Park; Z P Chen; J Leavitt
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

9.  Functional differences between L- and T-plastin isoforms.

Authors:  M Arpin; E Friederich; M Algrain; F Vernel; D Louvard
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

10.  Lamin A/C is a risk biomarker in colorectal cancer.

Authors:  Naomi D Willis; Thomas R Cox; Syed F Rahman-Casañs; Kim Smits; Stefan A Przyborski; Piet van den Brandt; Manon van Engeland; Matty Weijenberg; Robert G Wilson; Adriaan de Bruïne; Christopher J Hutchison
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

View more
  8 in total

1.  Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype.

Authors:  Corey Ruhno; Vicki L McGovern; Matthew R Avenarius; Pamela J Snyder; Thomas W Prior; Flavia C Nery; Abdurrahman Muhtaseb; Jennifer S Roggenbuck; John T Kissel; Valeria A Sansone; Jennifer J Siranosian; Alec J Johnstone; Pann H Nwe; Ren Z Zhang; Kathryn J Swoboda; Arthur H M Burghes
Journal:  Hum Genet       Date:  2019-02-20       Impact factor: 4.132

2.  Low expression of DCXR protein indicates a poor prognosis for hepatocellular carcinoma patients.

Authors:  Xiaofeng Hang; Zhiqin Wu; Kaijian Chu; Guanzhen Yu; Haoran Peng; Haiguang Xin; Xiaohui Miao; Junxue Wang; Wensheng Xu
Journal:  Tumour Biol       Date:  2016-09-22

Review 3.  Plastin 3 in health and disease: a matter of balance.

Authors:  Lisa Wolff; Eike A Strathmann; Ilka Müller; Daniela Mählich; Charlotte Veltman; Anja Niehoff; Brunhilde Wirth
Journal:  Cell Mol Life Sci       Date:  2021-05-23       Impact factor: 9.261

4.  Plastin 3 Expression Does Not Modify Spinal Muscular Atrophy Severity in the ∆7 SMA Mouse.

Authors:  Vicki L McGovern; Aurélie Massoni-Laporte; Xueyong Wang; Thanh T Le; Hao T Le; Christine E Beattie; Mark M Rich; Arthur H M Burghes
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

5.  Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients.

Authors:  Michael Stotz; Joanna Szkandera; Julia Seidel; Tatjana Stojakovic; Hellmut Samonigg; Daniel Reitz; Thomas Gary; Peter Kornprat; Renate Schaberl-Moser; Gerald Hoefler; Armin Gerger; Martin Pichler
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

Review 6.  Early-Onset Osteoporosis: Rare Monogenic Forms Elucidate the Complexity of Disease Pathogenesis Beyond Type I Collagen.

Authors:  Alice Costantini; Riikka E Mäkitie; Markus A Hartmann; Nadja Fratzl-Zelman; M Carola Zillikens; Uwe Kornak; Kent Søe; Outi Mäkitie
Journal:  J Bone Miner Res       Date:  2022-09-11       Impact factor: 6.390

7.  The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia.

Authors:  Arne Velthaus; Kerstin Cornils; Jan K Hennigs; Saskia Grüb; Hauke Stamm; Daniel Wicklein; Carsten Bokemeyer; Michael Heuser; Sabine Windhorst; Walter Fiedler; Jasmin Wellbrock
Journal:  Cancers (Basel)       Date:  2019-10-26       Impact factor: 6.639

8.  Plastin-3 is a diagnostic and prognostic marker for pancreatic adenocarcinoma and distinguishes from diffuse large B-cell lymphoma.

Authors:  Fei Xiong; Guan-Hua Wu; Bing Wang; Yong-Jun Chen
Journal:  Cancer Cell Int       Date:  2021-08-04       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.